WASHINGTON, Jan. 19,
2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc.
(Vanda) (Nasdaq: VNDA) today announced that the United States Court of Federal Claims in
Washington, D.C. denied in part
the government's motion to dismiss Vanda's claim against
the United States for the Food and
Drug Administration's (FDA) uncompensated taking of Vanda's
trade secrets and confidential information (Vanda
Pharmaceuticals Inc. v. USA,
case no. 1:23-cv-00629-AOB). Vanda is seeking compensation from
the United States for the takings
it contends occurred through the FDA's improper communication and
disclosure of trade secrets and confidential information to certain
generic drug manufacturers.
Vanda filed this lawsuit on May 1,
2023, and the United States
moved to dismiss. On January 8, 2024,
the Court held an oral argument on the government's motion. On
January 18, 2024, the Court denied
the government's motion in part, allowing Vanda's takings claim to
move forward.
Vanda now intends to engage in discovery to support its
claims.
About Vanda Pharmaceuticals Inc.
Vanda is a leading global biopharmaceutical company focused on
the development and commercialization of innovative therapies to
address high unmet medical needs and improve the lives of patients.
For more on Vanda Pharmaceuticals Inc., please visit
www.vandapharma.com and follow us on Twitter @vandapharma.
Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/federal-court-allows-vanda-pharmaceuticals-lawsuit-to-proceed-against-the-us-food-and-drug-administration-302039820.html
SOURCE Vanda Pharmaceuticals Inc.